A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera-Reference-Cited by-同舟云学术

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Published:2005-03-27 Issue:7037 Volume:434 Page:1144-1148
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

James Chloé,Ugo Valérie,Le Couédic Jean-Pierre,Staerk Judith,Delhommeau François,Lacout Catherine,Garçon Loïc,Raslova Hana,Berger Roland,Bennaceur-Griscelli Annelise,Villeval Jean Luc,Constantinescu Stefan N.,Casadevall Nicole,Vainchenker William

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature03546.pdf

Reference27 articles.

1. Spivak, J. L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin. Hematol. 41 (2 suppl. 3), 1–5 (2004)

2. Prchal, J. T. Polycythemia vera and other primary polycythemias. Curr. Opin. Hematol. 12, 112–116 (2005)

3. Spivak, J. L. Polycythemia vera: myths, mechanisms, and management. Blood 100, 4272–4290 (2002)

4. Prchal, J. F. & Axelrad, A. A. Bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290, 1382 (1974)

5. Casadevall, N. et al. Erythroid progenitors in polycythemia vera. Demonstration of their hypersensitivity to erythropoietin using serum-free cultures. Blood 59, 447–451 (1982)

Cited by 3040 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms;International Journal of Molecular Sciences;2024-09-12

2. Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A Review;Pharmaceutics;2024-09-04

3. Screening for Janus kinase-2 exon 12 mutations among Janus kinase-2 V617F-negative polycythemia vera suspected Iraqi patients;Iraqi Journal of Hematology;2024-09-02

4. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Structural basis of MPL activation by thrombopoietin;Blood Vessels, Thrombosis & Hemostasis;2024-09